Analytical validation of the 7-gene biosignature for prediction of recurrence risk and radiation therapy benefit for breast ductal carcinoma in situ

Analytical validation of the 7-gene biosignature for prediction of recurrence risk and radiation therapy benefit for breast ductal carcinoma in situ

PurposeDuctal carcinoma in situ (DCIS), is a noninvasive breast cancer, representing 20-25% of breast cancer diagnoses in the USA. Current treatment options for DCIS include mastectomy or breast-conserving surgery (BCS) with or without radiation therapy (RT), but optimal risk-adjusted treatment sele...

Full description

Bibliographic Details
Main Authors: David Dabbs, Karuna Mittal, Scott Heineman, Pat Whitworth, Chirag Shah, Jess Savala, Steven C. Shivers, Troy Bremer
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Oncology
Subjects:
DCIS - breast ductal carcinoma in situ
DCIS biomarkers and morphogenetic mechanisms
radiation therapy
analytical validation
radiogenomics
immunohistochemistry
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1069059/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1069059/full

Similar Items